Synthetic Biologics Reports 2021 First Quarter Operational Highlights and Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/7/2026

1. MRVL
2. ZS
3. PENG
4. STZ
5. NVDA
6. MSFT
7. SKYD
8. SPY
9. CRWV
10. CRBU

Go back to Synthetic Biologics Reports 2021 First Quarter Operational Highlights and Financial Results

Synthetic Biologics (SYN) Misses Q1 EPS by 11c

May 5, 2021 5:11 PM EDT

Synthetic Biologics (NYSE: SYN) reported Q1 EPS of ($0.13), $0.11 worse than the analyst estimate of ($0.02).

"During the first quarter of 2021 we remained diligently focused on advancing our portfolio of GI and microbiome-focused clinical programs and were pleased to announce the commencement of clinical trials for our SYN-004 and SYN-020 programs," said Steven A. Shallcross, Chief Executive Officer of Synthetic Biologics. "Enrollment in the SYN-004 Phase 1b/2a clinical trial in allogeneic hematopoietic cell transplant (HCT) recipients is underway at the Washington University School of Medicine in St. Louis ("Washington University") and the first... More